Institute of Bioengineering and Nanotechnology, The Nanos, Singapore.
Free Radic Res. 2009 Oct;43(10):899-912. doi: 10.1080/10715760903137002. Epub 2009 Aug 7.
A class of imidazolium salts (IMSs) is routinely used in organic synthetic chemistry as precursors to generate N-heterocyclic carbenes (NHCs) with catalytic activity. However, their biological properties are largely unknown. The current study investigates the biological activity of a typical NHC precursor DBZIM and its trimer TDBZIM in hepatic stellate cells (HSCs), which is an in vitro model for studying liver fibrosis. The results show that HSCs treated with IMSs have an enhanced GSH/GSSG ratio and a reduced level of reactive oxygen species (ROS), which may consequently contribute to the attenuation in gene expression of fibrogenic molecules such as smooth muscle actin-alpha (SMAA), transforming growth factor-beta 1 (TGF-beta1), procollagen alphaI(I) and fibronectin. Further, the in vivo experiments demonstrate that DBZIM is an anti-fibrotic agent in a mouse model of liver fibrosis. These findings suggest that the versatile IMSs could be a potential source for developing novel therapeutics to treat liver fibrosis and other fibrogenic disorders caused by oxidative stress and TGF-beta1 mal-signalling.
一类咪唑鎓盐(IMSs)在有机合成化学中被常规用作生成具有催化活性的 N-杂环卡宾(NHCs)的前体。然而,它们的生物学特性在很大程度上是未知的。本研究调查了典型的 NHC 前体 DBZIM 及其三聚体 TDBZIM 在肝星状细胞(HSCs)中的生物学活性,HSCs 是研究肝纤维化的体外模型。结果表明,用 IMSs 处理的 HSCs 具有增强的 GSH/GSSG 比值和降低的活性氧(ROS)水平,这可能导致成纤维分子如平滑肌肌动蛋白-α(SMAA)、转化生长因子-β1(TGF-β1)、原胶原αI(I)和纤连蛋白的基因表达减弱。此外,体内实验表明 DBZIM 是肝纤维化小鼠模型中的一种抗纤维化剂。这些发现表明,多功能的 IMSs 可能是开发新型治疗药物治疗肝纤维化和其他由氧化应激和 TGF-β1 信号异常引起的纤维变性疾病的潜在来源。